ESC 365 - Real world practices and outcomes in the management of heart failure patients with T2DM.

HFA Premium Access

Real world practices and outcomes in the management of heart failure patients with T2DM.

Session: Heart Failure, diabetes & SGLT2 inhibition: time to change practice?

Topic: Epidemiology, Prognosis, Outcome

Speaker: Professor C. Lam (Singapore, SG)

Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Boehringer Ingelheim

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Professor Carolyn S P Lam

Duke-NUS Graduate Medical School Singapore, Singapore (Singapore)

166 presentations

57 followers

4 more presentations in this session

The essentials for diabetes and heart failure.

Speaker: Professor M. Cowie (Cambridge, GB)

Why could patients with heart failure and T2DM benefit from SGLT2 inhibition?

Speaker: Professor S. Verma (Toronto, CA)

The future of SGLT2 inhibition in heart failure: managing patients without T2DM?

Speaker: Professor A. Voors (Groningen, NL)

Panel discussion - Heart Failure, diabetes & SGLT2 inhibition: time to change practice?

Speaker: Professor M. Cowie (Cambridge, GB)

Access the full session

Heart Failure, diabetes & SGLT2 inhibition: time to change practice?

Speakers: Professor C. Lam, Professor M. Cowie, Professor S. Verma, Professor A. Voors, Professor M. Cowie

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources